VCBeat Health Contact Us
Home Ivonescimab OS Data Excellence No Accident — Summit Therapeutics $15.3B Valuation Still Holds Promise

Ivonescimab OS Data Excellence No Accident — Summit Therapeutics $15.3B Valuation Still Holds Promise

Jun 01, 2026 00:15 CST Updated 00:49
Akeso

Innovative Antibody Drug Developer

Summit Therapeutics

Pharmaceutical Research and Development Company